Company Overview of Boehringer Ingelheim (Canada) Ltd./Ltée.
Boehringer Ingelheim (Canada) Ltd./Ltée. is engaged in researching and developing new drugs and treatments that represent major therapeutic advance. It offers therapeutic options for diseases and conditions, such as chronic obstructive pulmonary disease (COPD), high blood pressure, stroke, depression, benign prostatic hyperplasia, Parkinson's disease, HIV/AIDS, complications of blood clotting, restless leg syndrome, and continue extensive research in cancer, virology, stroke prevention in atrial fibrillation, diabetes, and respiratory diseases. The company provides prescription and non-prescription medicines for a range of conditions. It also offers Metacam, solution for pain management and ...
5180 South Service Road
Burlington, ON L7L 5H4
Founded in 1972
Key Executives for Boehringer Ingelheim (Canada) Ltd./Ltée.
Chairman of Board of Managing Directors, Head of Pharma Research, Development & Medicine and Head of Corporate Board Division
Head of Corporate Board Divisions Biopharmaceuticals/Operations and Member of the Board of Managing Directors
Head of Corporate Board Division, Pharma Marketing and Sales
Managing Director of Corporate Board Divisions - Finance and Human Resources
Director of Veterinary Medical Affairs
Compensation as of Fiscal Year 2014.
Boehringer Ingelheim (Canada) Ltd./Ltée. Key Developments
Boehringer Ingelheim (Canada) Ltd. Announces Health Canada Approval for Pradaxa
Sep 4 14
Boehringer Ingelheim (Canada) Ltd. announced that on June 26, Health Canada approved Pradaxa(R) (dabigatran etexilate) for the treatment of venous thromboembolism events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and for the prevention of recurrent DVT and PE. Venous thromboembolism (VTE) is the third most common cause of vascular death after myocardial infarction (heart attack) and stroke. Deep vein thrombosis occurs when a blood clot forms deep in the veins (between the muscles). If left untreated, the blood clots can increase in size, break off and travel to the lungs, causing a PE. Health Canada's approval is based on results from four robust phase III clinical trials involving almost 10,000 patients that demonstrated the efficacy of Pradaxa(R) 150 mg twice daily in the treatment and prevention of recurrent DVT and PE. Trial data also showed a 92% reduction in the risk of recurrent blood clots versus placebo.
Boehringer Ingelheim Announces New Data from its Phase III Clinical Trial Program
Nov 18 13
Boehringer Ingelheim announced new data from its Phase III clinical trial program, STARTVerso(TM), which evaluates faldaprevir, a molecule discovered in Canada, in combination with pegylated interferon and ribavirin. Patients with genotype-1 (GT-1) hepatitis C (HCV) who have not received previous treatment (treatment-naïve: STARTVerso(TM)1&2), treatment-experienced patients (STARTVerso(TM)3), and HIV co-infected patients (STARTVerso(TM)4) participated in this study program. The results from these and additional studies were presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting(R), which took place November 1 to 5 in Washington, D.C. In STARTVerso(TM)1&2, 84% of treatment-naïve patients receiving faldaprevir were able to shorten total time on treatment from 48 to 24 weeks; 83% of these patients achieved viral cure (SVR12^).Overall, 73% and 72% of patients achieved SVR12 with faldaprevir 120mg and 240mg regimens respectively. Interim results from STARTVerso(TM)4 showed that 74% of patients with HCV/HIV co-infection treated with faldaprevir had undetectable HCV 4 weeks after the conclusion of treatment (SVR4); a response rate similar to that seen with HCV mono-infection. Additionally, treatment of difficult-to-cure patients who have relapsed on previous HCV treatment (STARTVerso(TM)3) demonstrated viral cure rates of 70% with faldaprevir after 12 weeks. In the same study, patients who partially responded and those who showed no response to previous treatment achieved viral cure rates of up to 58% and 33%, respectively after 12 weeks.
Boehringer Ingelheim (Canada) Ltd./Ltée. and Eli Lilly and Company Announce Results of Two Phase III 24-Week Clinical Trials of the Investigational Agent Empagliflozin Added to Metformin in People with Type 2 Diabetes Mellitus
Jun 22 13
Boehringer Ingelheim and Eli Lilly and Company announced results of two Phase III 24-week clinical trials of the investigational agent empagliflozin added to metformin with and without the addition of sulphonylurea, in people with type 2 diabetes mellitus (T2DM). The results showed statistically significant improvements in blood glucose as measured by reductions in HbA1c (average blood glucose) after 24 weeks among people who received empagliflozin.(1,2). Empagliflozin is a member of the sodium glucose co-transporter 2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2DM. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose reabsorption by the kidney. In this 24-week randomised, double-blind, placebo-controlled trial, the addition of empagliflozin to a background of metformin plus sulphonylurea therapy showed a placebo-adjusted reduction in HbA1c of 0.64% and 0.59% (p<0.001) for empagliflozin 10mg (n=225) and 25mg (n=216), respectively, compared with placebo (n=225).(2) The study also showed a statistically significant placebo-adjusted reduction at 24 weeks in mean daily glucose concentration of 0.56mmol/L and 0.72mmol/L (p<0.001) with empagliflozin 10mg and 25mg, respectively.(2) Reductions in body weight were significantly greater with the addition of empagliflozin to metformin plus sulphonylurea (change in body weight of 1.75 kg, 10mg; and 1.99 kg, 25mg; p<0.001). Drug-related adverse events were reported by 24.1%, 19.8% and 15.5% of patients on empagliflozin 10mg, empagliflozin 25mg and placebo, respectively. Confirmed hypoglycaemia was reported in 16.1% of patients on empagliflozin 10mg, 11.5% on empagliflozin 25mg and 8.4% on placebo; none of which required assistance. Adverse events consistent with urinary tract infection were reported in 10.3% of patients on empagliflozin 10mg, 8.3% on empagliflozin 25mg and 8.0% on placebo. Adverse events consistent with genital infection were reported in 2.7% of patients on empagliflozin 10mg, 2.3% on empagliflozin 25mg and 0.9% on placebo. Empagliflozin is being investigated in adults with T2DM in a Phase III clinical trial program that plans to enrol more than 14,500 patients. This program comprises more than 10 multinational clinical trials, including a large cardiovascular outcomes trial.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|